RAGE against the glycation machine in synucleinopathies : time to explore new questions

• Autor(a) principal: Gelain, Daniel Pens
• Data de Publicação: 2023
• Outros Autores: Bittencourt, Reykla Ramon, Mendes, Luiz Filipe Bastos, Moreira, Jose Claudio Fonseca, Outeiro, Tiago Fleming
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/263898
• topic: Doenças neurodegenerativas; Doença de Parkinson; Alfa-sinucleína; Receptor para produtos finais de glicação avançada; Sinucleinopatias; α-synuclein; Glycation; Parkinson’s disease; RAGE; Synucleinopathies

Oligomerization and aggregation of misfolded forms of α-synuclein are believed to be key molecular mechanisms in Parkinson’s disease (PD) and other synucleinopathies, so extensive research has attempted to understand these processes. Among diverse post-translational modifications that impact α-synuclein aggregation, glycation may take place at several lysine sites and modify α-synuclein oligomerization, toxicity, and clearance. The receptor for advanced glycation end products (RAGE) is considered a key regulator of chronic neuroinflammation through microglial activation in response to advanced glycation end products, such as carboxy-ethyl-lysine, or carboxy-methyl-lysine. The presence of RAGE in the midbrain of PD patients has been reported in the last decades and this receptor was proposed to have a role in sustaining PD neuroinflammation. However, different PD animal models demonstrated that RAGE is preferentially expressed in neurons and astrocytes, while recent evidence demonstrated that fibrillar, non-glycated α-synuclein binds to RAGE. Here, we summarize the available data on α-synuclein glycation and RAGE in the context of PD, and discuss about the questions yet to be answered that may increase our understanding of the molecular bases of PD and synucleinopathies.